Contracts › HDTRA124C0008
HDTRA124C0008: Generation of a Novel Antibody-Antibiotic Conjugate As a Combination Therapy Platform to Treat Melioidosis or Plague.
Awarded to Ministry of Defence by Defense Threat Reduction Agency.
$5.6Mobligated
$8.4Mpotential value
09 June 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | HDTRA124C0008 |
|---|---|
| Awardee | Ministry of Defence |
| Awarding agency | Defense Threat Reduction Agency |
| Awarding office | DEFENSE THREAT REDUCTION AGENCY |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AC32 National Defense R&D Services; Defense-Related Activities; Applied Research |
| Offers received | 1 |
| Period of performance | 10 June 2024 to 09 June 2027 |
| Potential end | 09 December 2029 |
| Estimated recompete solicitation | ~Q4 2026 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record